SCHEMBL5374028

SCHEMBL5374028

COC(=O)CSCC#CCOCCc1nc(-c2ccc(C)cc2)oc1C

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.49
SMN1; SMN2 Q16637 10/20 0.48
ALDH1A1 P00352 6/20 0.48
POLB P06746 3/20 0.48
HSD17B10 Q99714 3/20 0.48
HPGD P15428 2/20 0.48
KDM4E B2RXH2 5/20 0.47
LMNA P02545 2/20 0.47
MAPT P10636 7/20 0.46
PKM P14618 1/20 0.46
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
PPARG P37231 3/20 0.44
PPARA Q07869 3/20 0.44
PPARD Q03181 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5377424 0.92 PPARG (0.48) SMN1; SMN2HSD17B10KDM4EMAPTPPARG
SCHEMBL5375744 0.92 MAPT (0.50) RXFP1SMN1; SMN2ALDH1A1POLBHSD17B10
SCHEMBL5365636 0.91 RXFP1 (0.46) RXFP1SMN1; SMN2ALDH1A1POLBHSD17B10
SCHEMBL5367857 0.90 PPARG (0.48) RXFP1SMN1; SMN2ALDH1A1POLBHSD17B10
SCHEMBL5373806 0.86 HSD17B10 (0.39) RXFP1SMN1; SMN2ALDH1A1POLBHSD17B10
SCHEMBL5376066 0.86 MAPK1 (0.50) SMN1; SMN2ALDH1A1HSD17B10HPGDKDM4E
SCHEMBL5377212 0.83 PPARG (0.53) HPGDKDM4EPPARGPPARAPPARD
SCHEMBL6693789 0.83 SMN1; SMN2 (0.43) RXFP1SMN1; SMN2ALDH1A1POLBHSD17B10
SCHEMBL6693786 0.83 SMN1; SMN2 (0.43) RXFP1SMN1; SMN2ALDH1A1POLBHSD17B10
SCHEMBL5369422 0.82 HSD17B10 (0.53) RXFP1SMN1; SMN2ALDH1A1POLBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040087636-A1 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient ONO PHARMACEUTICAL CO., LTD. 2004-05-06 US claimed
US-6664281-B1 Oxazol-4-yl-alkoxy- or alkthioxy- functionality; peroxisome proliferator activated receptor regulators ONO PHARMACEUTICAL CO., LTD. (JP) 2003-12-16 US claimed
EP-1108713-A1 CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-06-20 EP claimed
US-7241784-B2 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-10 US disclosed
US-7241784-B2 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-10 US disclosed
US-7241784-B2 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-10 US disclosed
US-20040087636-A1 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient ONO PHARMACEUTICAL CO., LTD. 2004-05-06 US disclosed
US-6664281-B1 Oxazol-4-yl-alkoxy- or alkthioxy- functionality; peroxisome proliferator activated receptor regulators ONO PHARMACEUTICAL CO., LTD. (JP) 2003-12-16 US disclosed
EP-1108713-A1 CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-06-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087636-A1 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient PPARA, PPARG, PPARD RXFP1 1167/4885SMN1; SMN2 4797/4885ALDH1A1 252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.